Hepatocellular Carcinoma

Phase III Trials Begin for Thymitaq in Liver Cancer

Published in Hepatitis Weekly, August 28th, 2000

Zarix, Inc., Berwyn, Pennsylvania, announced progress on its Thymitaq (nolatrexed dihydrochloride) clinical trial program following recent correspondence with the U.S. Food and Drug Administration (FDA).

Thymitaq, a thymidylate synthase inhibitor, is being developed to treat several different cancers, with an initial emphasis in hepatocellular carcinoma (liver cancer).

Zarix announced that the FDA has indicated that the design of the pivotal Phase III trial for Thymitaq for the treatment of unresectable hepatocellular carcinoma is acceptable. This multi-center clinical study will be conducted as a global program with clinical study sites in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-08-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry